Abstract
Respiratory diseases constitute a huge burden in our society, and the global respiratory drug market currently grows at an annual rate between 4% and 6%. Inhalation is the preferred administration method for treating respiratory diseases, as it: (i) delivers the drug directly at the site of action, resulting in a rapid onset; (ii) is painless, thus improving patients’ compliance; and (iii) avoids first-pass metabolism reducing systemic side effects. Inhalation occurs through the mouth, with the drug generally exerting its therapeutic action in the lungs. In the most recent years, orally inhaled drugs (OIDs) have found application also in the treatment of systemic diseases. OIDs development, however, currently suffers of an overall attrition rate of around 70%, meaning that seven out of 10 new drug candidates fail to reach the clinic. Our commentary focuses on the reasons behind the poor OIDs translation into clinical products for the treatment of respiratory and systemic diseases, with particular emphasis on the parameters affecting the predictive value of animal preclinical tests. We then review the current advances in overcoming the limitation of animal animal-based studies through the development and adoption of in vitro, cell-based new approach methodologies (NAMs).
Funder
Center for Alternatives to Animal Testing, Johns Hopkins Bloomberg School of Public Health
European Union HORIZON 2020 Framework Programme
Subject
General Veterinary,Animal Science and Zoology
Reference140 articles.
1. Asthmahttps://www.who.int/news-room/q-a-detail/asthma
2. Chronic Obstructive Pulmonary Disease (COPD)https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-
3. CFFhttps://www.cff.org/What-is-CF/About-Cystic-Fibrosis/
4. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
5. Tuberculosishttps://www.who.int/news-room/fact-sheets/detail/tuberculosis
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献